MA47437A - Procédés de traitement d'infections fongiques - Google Patents
Procédés de traitement d'infections fongiquesInfo
- Publication number
- MA47437A MA47437A MA047437A MA47437A MA47437A MA 47437 A MA47437 A MA 47437A MA 047437 A MA047437 A MA 047437A MA 47437 A MA47437 A MA 47437A MA 47437 A MA47437 A MA 47437A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment methods
- fungal infection
- infection treatment
- fungal
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452643P | 2017-01-31 | 2017-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47437A true MA47437A (fr) | 2019-12-11 |
Family
ID=63040056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047437A MA47437A (fr) | 2017-01-31 | 2018-01-31 | Procédés de traitement d'infections fongiques |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190374601A1 (fr) |
| EP (1) | EP3577129A1 (fr) |
| JP (1) | JP2020505427A (fr) |
| CN (1) | CN110753698A (fr) |
| MA (1) | MA47437A (fr) |
| WO (1) | WO2018144600A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2865791C (fr) | 2011-03-03 | 2019-10-08 | Cidara Therapeutics, Inc. | Agents antifongiques et leurs utilisations |
| SI3677252T1 (sl) | 2012-03-19 | 2024-02-29 | Cidara Therapeutics, Inc. | Sheme odmerjanja za spojine iz razreda ehinokandinov |
| US10369188B2 (en) | 2016-01-08 | 2019-08-06 | Cidara Therapeutics, Inc. | Methods for preventing and treating pneumocystis infections |
| JP7224916B2 (ja) | 2016-03-16 | 2023-02-20 | シダラ セラピューティクス インコーポレーテッド | 真菌感染の処置のための投薬レジメン |
| MA49576A (fr) | 2017-07-12 | 2021-04-07 | Cidara Therapeutics Inc | Compositions et méthodes pour le traitement d'infections fongiques |
| EP3806882A4 (fr) | 2018-06-15 | 2022-03-23 | Cidara Therapeutics, Inc. | Synthèse d'un agent antifongique d'échinocandine |
| US12060439B2 (en) | 2018-10-25 | 2024-08-13 | Napp Pharmaceutical Group Limited | Polymorph of echinocandin antifungal agent |
| AU2021234626A1 (en) * | 2020-03-13 | 2022-09-29 | AHV International B.V. | Compositions for disrupting biofilm formation and for treating biofilm-related disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005053613A2 (fr) * | 2003-11-26 | 2005-06-16 | Combinatorx, Inc. | Combinaisons de traitement d'infections fongiques |
| JP2011518844A (ja) * | 2008-04-25 | 2011-06-30 | ナノバイオ コーポレーション | 真菌、酵母および糸状菌感染症を治療するためのナノエマルション |
| CA2865791C (fr) * | 2011-03-03 | 2019-10-08 | Cidara Therapeutics, Inc. | Agents antifongiques et leurs utilisations |
| CN102293771A (zh) * | 2011-06-30 | 2011-12-28 | 北京大学第一医院 | 一种治疗浅部真菌感染的药物组合物及其应用 |
| SI3677252T1 (sl) * | 2012-03-19 | 2024-02-29 | Cidara Therapeutics, Inc. | Sheme odmerjanja za spojine iz razreda ehinokandinov |
| US20160213742A1 (en) * | 2013-09-04 | 2016-07-28 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of fungal infections |
-
2018
- 2018-01-31 MA MA047437A patent/MA47437A/fr unknown
- 2018-01-31 US US16/482,043 patent/US20190374601A1/en not_active Abandoned
- 2018-01-31 JP JP2019541442A patent/JP2020505427A/ja active Pending
- 2018-01-31 WO PCT/US2018/016236 patent/WO2018144600A1/fr not_active Ceased
- 2018-01-31 EP EP18748583.4A patent/EP3577129A1/fr not_active Withdrawn
- 2018-01-31 CN CN201880022357.6A patent/CN110753698A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190374601A1 (en) | 2019-12-12 |
| EP3577129A1 (fr) | 2019-12-11 |
| WO2018144600A1 (fr) | 2018-08-09 |
| JP2020505427A (ja) | 2020-02-20 |
| CN110753698A (zh) | 2020-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45192A (fr) | Traitement d'association | |
| MA47437A (fr) | Procédés de traitement d'infections fongiques | |
| EP3439960A4 (fr) | Module de traitement d'air | |
| EP3426250A4 (fr) | Procédés de traitement | |
| EP3601536A4 (fr) | Procédés de traitement | |
| EP3613073A4 (fr) | Traitement de puces | |
| MA50056A (fr) | Procédés de traitement de tumeur | |
| EP3474972A4 (fr) | Systèmes et procédés de traitement de l'air | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| EP2953624A4 (fr) | Procédés de traitement d'infections microbiennes, y compris la mammite | |
| EP3390357A4 (fr) | Composés de biarylmonobactame et procédés d'utilisation correspondants pour le traitement d'infections bactériennes | |
| EP3285776A4 (fr) | Méthodes de traitement d'infections bactériennes | |
| EP3625971A4 (fr) | Traitement d'audio spatial | |
| EP3409744A4 (fr) | Agent de traitement de surface | |
| MA52630A (fr) | Procédés de traitement de l'hémophilie a | |
| EP3443094A4 (fr) | Procédés de réduction de l'expression de c9orf72 | |
| EP3512524A4 (fr) | Méthodes et compositions de traitement d'infections virales | |
| PL3600374T3 (pl) | Leczenie zakażenia układu oddechowego | |
| EP3431566A4 (fr) | Agent de traitement de surface | |
| MA46062A (fr) | Traitement par ascaroside de l'oesophagite à éosinophiles | |
| EP3914235A4 (fr) | Procédés de traitement de la dépendance | |
| EP3399995A4 (fr) | Procédés de prévention et de traitement d'infections à pneumocystis | |
| EP3705545A4 (fr) | Composition de traitement de surface | |
| EP3454793A4 (fr) | Bobines de traitement d'anévrisme | |
| EP3651801A4 (fr) | Compositions et méthodes pour le traitement d'infections fongiques |